MBX Biosciences (MBX) said Friday that Chief Financial Officer Richard Bartram will step down, effective March 15, and that John Smither has been named interim CFO.
The company said in a regulatory filing that Bartram will serve as a consultant to the company following his resignation and that it has begun a search for a new CFO.
MBX said Bartram's departure is not related to any disagreement with the company or its auditors.
Smither is a former CFO of Arcutis Biotherapeutics (ARQT) and is currently a member of the boards of NewAmsterdam Pharma (NAMS) and Genelux Corporation (GNLX).
Shares of MBX Biosciences were 1.3% lower in recent premarket trading.
Comments